4-hydroxyphenylglycine has been researched along with Heart Failure in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maisch, B; Rupp, H; Rupp, TP | 1 |
| Chandler, MP; d'Agostino, C; Gupte, S; Hintze, TH; Linke, A; Lionetti, V; Penn, MS; Recchia, FA; Stanley, WC; Young, ME | 1 |
2 other study(ies) available for 4-hydroxyphenylglycine and Heart Failure
| Article | Year |
|---|---|
Fatty acid oxidation inhibition with PPARalpha activation (FOXIB/PPARalpha) for normalizing gene expression in heart failure?
Topics: Animals; Carnitine O-Palmitoyltransferase; Clinical Trials as Topic; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Gene Expression Regulation; Glycine; Heart Failure; Humans; Hypoglycemic Agents; Oxidation-Reduction; PPAR alpha | 2005 |
Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure.
Topics: Animals; Blotting, Western; Cardiac Pacing, Artificial; Carnitine O-Palmitoyltransferase; Dogs; Enzyme Inhibitors; Fatty Acids; Gene Expression; Glycine; Heart Failure; Male; Myocardium; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptors; Reverse Transcriptase Polymerase Chain Reaction; Stroke Volume; Time Factors; Ventricular Remodeling | 2005 |